Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01931176 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01931176 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 14 participants.
The verdict
NCT01931176, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Dengue viruses can cause dengue fever and other more serious illnesses. The purpose of this study is to evaluate the safety and immune response to a dengue virus vaccine.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL rDEN2Δ30-7169 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01931176
The ClinicalTrials.gov registry entry for NCT01931176 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01931176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01931176 about?
NCT01931176 is a clinical study titled "Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults". Dengue viruses can cause dengue fever and other more serious illnesses. The purpose of this study is to evaluate the safety and immune response to a dengue virus vaccine.
What is the current status of trial NCT01931176?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2013-06. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01931176?
The interventions under investigation include: Placebo (BIOLOGICAL), rDEN2Δ30-7169 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01931176?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.